A Phase II Trial of Personalized Immunotherapy in Patients (pts) with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M HNSCC) That Have Progressed on Prior Immunotherapy

被引：0
|
作者：
Zandberg, D. P. [1 ]
Chen, J. [2 ]
Tatsuoka, C. [2 ]
Normolle, D. P. [3 ]
Ohr, J. [2 ]
Isett, B.
Rahman, Z. [2 ,5 ]
Fenton, M. [6 ]
Gooding, W. [7 ]
Vujanovic, L. [4 ]
Bao, R. [8 ]
Marsh, C. [2 ]
Seastone, D. [2 ]
Gorantla, V. [1 ]
Pabla, S. [9 ]
Conroy, J.
Ferris, R. L. [5 ]
机构：
[1] Univ Pittsburgh, Div Hematol & Oncol, Dept Med, Med Ctr, Pittsburgh, PA USA
[2] UPMC Hillman Canc Ctr, Pittsburgh, PA USA
[3] Univ Pittsburgh, Canc Inst, Pittsburgh, PA USA
[4] Univ Pittsburgh, Pittsburgh, PA USA
[5] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[6] UPMC, Pittsburgh, PA USA
[7] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA USA
[8] UPMC, Div Hematol Oncol, Hillman Canc Ctr, Pittsburgh, PA USA
[9] Labcorp Oncol, Buffalo, NY USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 118卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4
引用
收藏
页码：E4 / E4
页数：1
相关论文
共 50 条
  • [41] Combination immunotherapy of squamous cell carcinoma of the head and neck - A phase 2 trial
    Barrera, JL
    Verastegui, E
    Meneses, A
    Zinser, J
    de la Garza, J
    Hadden, JW
    ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2000, 126 (03) : 345 - 351
  • [42] Randomized, phase II study of ficlatuzumab with or without cetuximab in patients with pan-refractory, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Bauman, Julie E.
    Roe, Denise
    Saba, Nabil F.
    Bauman, Jessica Ruth
    Kaczmar, John M.
    Burtness, Barbara
    Muzaffar, Jameel
    Julian, Ricklie Ann
    Wang, Steven
    Bearelly, Shethal
    Baker, Audrey
    Steuer, Conor Ernst
    Bhatia, Aarti K.
    Giri, Anshu
    Caulin, Carlos
    Stabile, Laura P.
    Centuori, Sara
    Chung, Christine H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [43] Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of phase II study.
    Chung, Christine H.
    Bonomi, Marcelo Raul
    Steuer, Conor Ernst
    Schell, Michael J.
    Li, Jiannong
    Johnson, Matthew
    Masannat, Jude
    Hernandez-Prera, Juan C.
    McMullen, Caitlin
    Wadsworth, J.
    Patel, Krupal
    Kish, Julie Ann
    Muzaffar, Jameel
    Kirtane, Kedar
    Rocco, James William
    Saba, Nabil F.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [44] Phase II study of combination cisplatin, docetaxel and erlotinib in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC).
    Kim, E. S.
    Kies, M. S.
    Glisson, B. S.
    Ginsberg, L. E.
    Holsinger, F. C.
    Burke, B. J.
    Truong, M.
    Tsao, A. S.
    Hong, W. K.
    Lippman, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 285S - 285S
  • [45] Phase II Study of Saracatinib (AZD0530) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
    Fury, Matthew G.
    Baxi, Shrujal
    Shen, Ronglai
    Kelly, Katherine W.
    Lipson, Brynna L.
    Carlson, Diane
    Stambuk, Hilda
    Haque, Sofia
    Pfister, David G.
    ANTICANCER RESEARCH, 2011, 31 (01) : 249 - 253
  • [46] Preliminary efficacy and safety of camrelizumab combined with cetuximab and chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A phase II clinical trial.
    Ji, Dongmei
    Sang, Youzhou
    Liu, Xin
    Guo, Yanjing
    Yang, Yanan
    Chen, Guangliang
    Dong, Shu
    Wang, Yulong
    He, Xiayun
    Ying, Hongmei
    Lu, Xueguan
    Wang, Yu
    Hu, Chaosu
    Ji, Qinghai
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] Time of referral of patients (pts) with recurrent/metastatic (r/m) head and neck squamous cell cancer (HNSCC) to medical oncology and survival.
    Siano, Marco
    Espeli, Vittoria
    Desax, Marie-Claire
    Broglie, Martina Anja
    Joerger, Markus
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [48] The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
    Cohen, Ezra E. W.
    Bell, R. Bryan
    Bifulco, Carlo B.
    Burtness, Barbara
    Gillison, Maura L.
    Harrington, Kevin J.
    Quynh-Thu Le
    Lee, Nancy Y.
    Leidner, Rom
    Lewis, Rebecca L.
    Licitra, Lisa
    Mehanna, Hisham
    Mel, Loren K.
    Raben, Adam
    Sikora, Andrew G.
    Uppaluri, Ravindra
    Whitworth, Fernanda
    Zandberg, Dan P.
    Ferris, Robert L.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [49] Feasibility study of a personalized tumor membrane vesicle vaccine immunotherapy for head and neck squamous cell carcinoma (HNSCC)
    Bommireddy, Ramireddy
    Pack, Christopher D.
    Ramachandiran, Sampath
    Jacobsen, Kristen
    Reddy, Shaker J. C.
    Schmitt, Nicole C.
    Patel, Mihir R.
    Shi, Qiuying
    Steuer, Conor Ernst
    Saba, Nabil F.
    Selvaraj, Periasamy
    Shin, Dong Moon
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] Impact of antibiotic use and derived neutrophil to lymphocyte ratio (dNLR) in patients with recurrent/metastatic head and neck squamous cell cancer (R/M HNSCC) treated with immunotherapy
    Plana, M.
    Cefarelli, G.
    Guillen, P.
    Esteve, A.
    Oliva, M.
    Gonzalez, A.
    Brenes, J.
    Vilarino, N.
    Vilajosana, E.
    Gomez, V.
    Mesia, R.
    Taberna, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S675 - S675
12345